Unknown

Dataset Information

0

Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis.


ABSTRACT: OBJECTIVES:To examine the association between coffee, including caffeinated and decaffeinated coffee, with hepatocellular carcinoma (HCC) and assess the influence of HCC aetiology and pre-existing liver disease. DESIGN:We performed a systematic review and meta-analysis. We calculated relative risks (RRs) of HCC according to caffeinated and decaffeinated coffee consumption using a random-effects dose-response meta-analysis. We tested for modification of the effect estimate by HCC aetiology and pre-existing liver disease. We judged the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. RESULTS:We found 18 cohorts, involving 2 272 642 participants and 2905 cases, and 8 case-control studies, involving 1825 cases and 4652 controls. An extra two cups per day of coffee was associated with a 35% reduction in the risk of HCC (RR 0.65, 95%?CI 0.59 to 0.72). The inverse association was weaker for cohorts (RR 0.71, 95%?CI 0.65 to 0.77), which were generally of higher quality than case-control studies (RR 0.53, 95%?CI 0.41 to 0.69). There was evidence that the association was not significantly altered by stage of liver disease or the presence/absence of high alcohol consumption, high body mass index, type 2 diabetes mellitus, smoking, or hepatitis B and C viruses. An extra two cups of caffeinated and decaffeinated coffee (2 and 3 cohort studies, respectively) were associated with reductions of 27% (RR 0.73, 95%?CI 0.63 to 0.85) and 14% (RR 0.86, 95%?CI 0.74 to 1.00) in the risk of HCC. However, due to a lack of randomised controlled trials, potential publication bias and there being no accepted definition of coffee, the quality of evidence under the GRADE criteria was 'very low'. CONCLUSIONS:Increased consumption of caffeinated coffee and, to a lesser extent, decaffeinated coffee are associated with reduced risk of HCC, including in pre-existing liver disease. These findings are important given the increasing incidence of HCC globally and its poor prognosis.

SUBMITTER: Kennedy OJ 

PROVIDER: S-EPMC5730000 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis.

Kennedy Oliver John OJ   Roderick Paul P   Buchanan Ryan R   Fallowfield Jonathan Andrew JA   Hayes Peter Clive PC   Parkes Julie J  

BMJ open 20170509 5


<h4>Objectives</h4>To examine the association between coffee, including caffeinated and decaffeinated coffee, with hepatocellular carcinoma (HCC) and assess the influence of HCC aetiology and pre-existing liver disease.<h4>Design</h4>We performed a systematic review and meta-analysis. We calculated relative risks (RRs) of HCC according to caffeinated and decaffeinated coffee consumption using a random-effects dose-response meta-analysis. We tested for modification of the effect estimate by HCC a  ...[more]

Similar Datasets

| S-EPMC3898757 | biostudies-literature
| S-EPMC3396445 | biostudies-literature
| S-EPMC3180352 | biostudies-literature
| S-EPMC3502342 | biostudies-literature
| S-EPMC4123969 | biostudies-literature
| S-EPMC2809264 | biostudies-literature
| S-EPMC6249821 | biostudies-other
| S-EPMC4729676 | biostudies-literature
| S-EPMC5133591 | biostudies-literature
| S-EPMC11217372 | biostudies-literature